Physician profile
Thomas Searle
NPI 1669667010
$3,574.47
in general payments reported to CMS, 2019-2025
35 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $42.66 · 2021: $326 · 2022: $421 · 2023: $278 · 2024: $287 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,625 · Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,624.93 |
| Food and Beverage | $737.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,624.93 | 2025 | |
| Abbvie INC. | $316.53 | 2019-2022 | |
| Hologic Sales and Service, LLC | $241.01 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Astellas Pharma US INC | $128.75 | 2019-2025 | Veozah |
| Coopersurgical, INC. | $120.52 | 2021-2024 | Summit Doppler, Paragard T 380a |
| Pfizer INC. | $102.46 | 2019-2025 | |
| Organon LLC | $85.86 | 2022-2025 | Jada System |
| Therapeuticsmd, INC. | $82.48 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.57 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $77.35 | 2022-2025 | |
| Heron Therapeutics, INC. | $65.93 | 2022-2023 | Zynrelef |
| Lupin INC. | $63.18 | 2019 | |
| Amgen INC. | $56.62 | 2019 | |
| Allergan, INC. | $55.71 | 2021 | |
| Coloplast Corp | $49.26 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $40.53 | 2024-2025 | Injectafer |
| Evofem Biosciences, INC. | $35.49 | 2021 | |
| Optumhealth Care Solutions, LLC | $34.19 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Myovant Sciences INC. | $33.77 | 2022 | |
| Caldera Medical, INC | $29.87 | 2022 | |
| Exeltis, USA INC. | $25.76 | 2021-2023 | Slynd |
| Agile Therapeutics, INC. | $25.60 | 2021-2024 | Twirla |
| Pacira Pharmaceuticals Incorporated | $23.80 | 2022 | |
| Shield Therapeutics INC | $19.46 | 2024 | |
| Covidien LP | $19.06 | 2019 | |
| Sage Therapeutics, LLC | $18.15 | 2024 | |
| Lsi Solutions INC | $17.58 | 2023 | Fornisee |
| Exact Sciences Corporation | $15.80 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $15.73 | 2023 | Wegovy |
| Kci USA, INC. | $15.58 | 2023 | Prevena |
| Roche Diagnostics Corporation | $13.99 | 2019 | |
| Millicent US INC | $13.18 | 2019 | |
| Duchesnay USA Incorporated | $13.02 | 2019 | |
| Minerva Surgical, INC | $12.75 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Searle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.